Evaluation of the practicability of limited sampling strategies for the estimation of mycophenolic acid exposure in Chinese adult renal recipients

Therapeutic Drug Monitoring

Volumn 29, Issue 5, 2007, Pages 600-606

  Zicheng, Yu ^a   Xianghui, Wang ^a   Peijun, Zhou ^a   Da, Xu ^a   Weixia, Zhang ^a   Hongzhuan, Chen ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Limited sampling strategy; Mycophenolic acid; Renal transplantation; Therapeutic drug monitoring

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID; PREDNISONE;

ADULT; ALGORITHM; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; BLAND AND ALTMAN ANALYSIS; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LINEAR REGRESSION ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALIDITY; PRIORITY JOURNAL;

ADULT; ALGORITHMS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS;

EID: 34848906588     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181559f8a     Document Type: Article

References (31)

1. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation. 2005;80:181S-190S.
2. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet. 1995;345:1321-1325.
3. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 1995;60:225-232.
4. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation. 1996;61:1029-1037.
5. Meier-Kriesche HU, Steffen BJ, Hochberg AM, et al. Mycophenolate mofetil versus azathioprine therapy is associatedwith a significant protection against long-term renal allograft function deterioration. Transplantation. 2003;75:1341-1346.
6. Michel M, Jacques M, Djamila CE, et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem. 2001;47:88-94.
7. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998;64:672-683.
8. Van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomised double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999;68:261-266.
9. Oellerich M, Shipkova M, Schütz E, et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit. 2000;22:20-26.
10. Mourad M, Malaise J, Chaib Eddour D, et al. Pharmacokinetic basis of efficient and safe use of low mycophenolate mofetil (MMF, 1g/day) in combination with tacrolimus in kidney transplant patients. Clin Chem. 2001;47:1241-1248.
11. DeNofrio D, Loh E, Kao A, et al. Mycophenolic acid concentrations are associated with cardiac allograft rejection. J Heart Lung Transplant. 2000;19:1071-1076.
12. Shaw LM, Korecka M, Aradhye S, et al. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol. 2000;40:624-633.
13. van Hest RM, Mathot RA, Vulto AG, et al. Within-patient variability of mycophenolic acid exposure: therapeutic drug monitoring from a clinical point of view. Ther Drug Monit. 2006;28:31-34.
14. Yu ZC, Zhou PJ, Xu D, et al. Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patients. Br J Clin Pharmacol. 2006;62:446-452.
15. van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006;28:145-154.
16. van Hest RM, Hesselink DA, Vulto AG, et al. Individualization of mycophenolate mofetil dose in renal transplant recipients. Expert Opin Pharmacother. 2006;7:361-176.
17. Brown NW, Aw MM, Mieli-Vergani G, et al. Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. Ther Drug Monit. 2002;24:598-606.
18. Brunet M, Martorell J, Oppenheimer F, et al. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil. Transplant Int. 2000;13(Suppl 1):S301-S305.
19. Filler G, Mai I. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit. 2000;22:169-173.
20. Johnson AG, Rigby RJ, Taylor PJ, et al. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin Pharmacol Ther. 1999;66:492-500.
21. Le Guellec C, Buchler M, Giraudeau B, et al. Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy. Eur J Clin Pharmacol. 2002;57:805-811.
22. Pawinski T, Hale M, Korecka M, et al. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem. 2002;48:1497-1504.
23. Schutz E, Armstrong VW, Shipkova M, et al. Limited sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kidney recipients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Transplant Proc. 1998;30:1182-1184.
24. Shaw LM, Korecka M, DeNofrio D, et al. Pharmacokinetic, pharmacodyna -mic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem. 2001;34:17-22.
25. David-Neto E, Pereira Araujo LM, Sumita NM, et al. Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. Pediatr Nephrol. 2003;18:266-272.
26. Filler G. Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy. Transplant Int. 2004;17:120-125.
27. Filler G, Feber J, Lepage N, et al. Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children. Pediatr Transplantation. 2002;6:411-418.
28. Yeung S, Tong KL, Tsang WK, et al. Determination of mycophenolate area under the curve by limited sampling strategy. Transplant Proc. 2001; 33:1052-1053.
29. Yu ZC, Cai WM, Xu D, et al. HPLC determination of mycophenolate mofetil and its active metabolite mycophenolic acid in human plasma. Chin J Pharm Anal. 2005;25:381-384.
30. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
31. Kobayashi M, Saitoh H, Kobayashi M, et al. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther. 2004;309:1029-1035.